RIT approaches have also been tested in preclinical studies on CRC with significant effect alone or in association with either antibodies usually targeting transmembrane proteins (CEA, GPA33, EGFR) or chemotherapy [28–30]. The gene discussed is EGFR; the disease is colorectal carcinoma.